Why Sangamo Biosciences, Inc. Trounced the Market

Shares of Sangamo Biosciences are up more than 20% today on the news that HIV patients who were given Bristol-Myers Squibb's drug Cytoxan responded better to Sangamo's drug SB-728-T, which is made up of the patient's own genetically modified cells.

However, in this video, Motley Fool health-care analyst David Williamson points to a few things that investors need to keep in mind that should temper some of the enthusiasm. Firstly, the success story here was only two patients, and secondly, with Sangamo's drug, the virus is stabilized, but still detectable. Comparing this against current anti-viral drugs, which bring the virus down to undetectable levels, means Sangamo will still need to do better if it wants patients to switch. David takes a close look at the company in this video, discusses its financial situation, and points to some key trials coming up that will give investors a much better idea whether they should be jumping in on this stock.

Looking for more massive growth stocks in 2014?
They said it couldn't be done. But David Gardner has proved them wrong, time, and time, and time again, with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

The article Why Sangamo Biosciences, Inc. Trounced the Market originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story